Eloxx Pharmaceuticals, Inc. (ELOX): Cash & Equivalents
$4.79M
As of 2025-12-31
$61.96M
As of 2026-06-30
-37.1%
3-year compound annual growth
-28.0%
5-year compound annual growth
+13.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.79M | n/m | 2026-03-17, Balance as of period end |
| 2024-12-31 | $111.0K | -90.2% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $1.13M | -94.1% | 2026-03-17, Balance as of period end |
| 2022-12-31 | $19.21M | -54.6% | 2023-03-31, Balance as of period end |
| 2021-12-31 | $42.27M | +71.3% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $24.67M | +9.7% | 2022-03-30, Balance as of period end |
| 2019-12-31 | $22.49M | -53.7% | 2022-03-30, Balance as of period end |
| 2018-12-31 | $48.61M | +102.1% | 2021-03-12, Balance as of period end |
| 2017-12-31 | $24.05M | n/a | 2020-03-06, Balance as of period end |
| 2017-06-30 | $33.2K | n/a | 2017-10-13, Balance as of period end |
| 2016-12-31 | $2.21M | n/a | 2019-03-14, Balance as of period end |
| 2016-06-30 | $810.8K | n/a | 2017-10-13, Balance as of period end |
| 2015-12-31 | $1.37M | n/a | 2018-03-16, Balance as of period end |
| 2015-06-30 | $3.33M | -45.4% | 2017-10-13, Balance as of period end |
| 2014-06-30 | $6.11M | +281.4% | 2016-10-13, Balance as of period end |
| 2013-06-30 | $1.60M | -19.9% | 2015-10-09, Balance as of period end |
| 2012-06-30 | $2.00M | -44.6% | 2014-09-29, Balance as of period end |
| 2011-06-30 | $3.61M | -55.0% | 2013-09-11, Balance as of period end |
| 2010-06-30 | $8.03M | n/m | 2013-09-11, Balance as of period end |
| 2009-06-30 | $380.6K | n/a | 2012-10-26, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | $4.79M | n/m |
| Amgen Inc (AMGN) | 2025-12-31 | $9.13B | -23.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Vericel Corp (VCEL) | 2025-12-31 | $100.09M | +34.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
Compare ELOX, AMGN, RGEN, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗